Metagenomic Sequencing Market
Metagenomic Sequencing Market Analysis by Product & Service (Reagents & Consumables, Instruments, Services, Analysis & Data Interpretation Solutions), by Workflow (Sample Processing & Library Preparation, Sequencing, Data Processing & Analysis), by Technology (Shotgun Metagenomic Sequencing, 16S rRNA Sequencing, Metatranscriptomics, Whole-genome Sequencing & De Novo Assembly), by Application and by Region - Global Market Insights 2023 to 2033
Analysis of Metagenomic Sequencing Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Metagenomic Sequencing Market Outlook (2023 to 2033)
Newly-released metagenomic sequencing market analysis report by Fact.MR reveals that global revenue of Metagenomic Sequencing Market in 2022 was held at US$ 1.2 Billion. With 17.6% projected growth from 2023 to 2033, the market is expected to reach a valuation of US$ 7.1 Billion by the end of the forecast period.
Reagents & Consumables are expected to be the highest revenue-generating type in the market, projected to grow at a CAGR of over 17.4% from 2023 to 2033.
Global Metagenomic Sequencing Market Size 2022
US$ 1.2 Billion
Global Metagenomic Sequencing Market Size at End of Forecast (2033)
US$ 7.1 Billion
Global Metagenomic Sequencing Market CAGR (2023 to 2033)
U.S. Metagenomic Sequencing Market CAGR (2023 to 2033)
Key Companies Covered
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Revenue of Metagenomic Sequencing Market from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033
As per the research of the metagenomic sequencing market by Fact.MR - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 15.3% CAGR. With an absolute dollar opportunity of US$ 5.7 Billion, the market is projected to reach a valuation of US$ 7.1 Billion by 2033.
What are the Key Drivers Influencing Market Expansion?
The key drivers influencing market expansion include increased demand for microbiome research, technological advancement, growing applications in diverse fields, increasing investments in R&D, increasing awareness about precision medicine, and the prevalence of chronic diseases.
Metagenomic sequencing is used to study genetic material collected from environmental samples, such as soil, water, and air, as well as from biological samples, such as feces or skin swabs. The process of extracting DNA or RNA from a sample and sequencing the genetic material using high-throughput sequencing technologies such as Illumina or PacBio sequencing is known as metagenomic sequencing. The human microbiome plays a critical role in human health and disease, and researchers are increasingly interested in studying its composition and function. Metagenomic sequencing provides a powerful tool for investigating the microbiome, driving demand for this technology.
According to research, sepsis is a life-threatening condition caused by a systemic infection. In 2017, over 48.9 million sepsis cases were diagnosed and 11 million deaths were reported worldwide. Metagenomic sequencing can cause to identify the causative agents and used for the treatment. This is expected to influence the market growth.
Meningitis is a serious disease that can be caused by bacteria, viruses, or other microorganisms. According to the World Health Organization (WHO), there were over 2.8 million cases of meningitis and about 271 thousand deaths worldwide in 2019. Metagenomic sequencing of cerebrospinal fluid can help to identify the cause of the infection which is expected to lead to market growth in the upcoming years.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Region is projected to Offer Significant growth in the Market?
North America is a prominent shareholder of the market with a market size of US$ 493 million in 2022 and is estimated to reach US$ 575 million in 2023. It is projected that the region will have a market worth US$ 2.9 billion by 2033.
Sickle cell disease (SCD) is the most common disease in the United States, affecting 1 in 500 Americans. And over 3 million infants are born with sickle cell anemia annually. Meltagenomic sequencing is used for diagnosis, treatment, and prevention of sickle cell disease and other chronic illnesses. The increase in sickle cell incidence has been influencing the growing need for metagenomic sequencing.
Country-Wise Analysis :
United States Metagenomic Sequencing Market Analysis :
The market in the United States is expected to grow to be worth US$ 2.5 Billion by 2033, with an absolute dollar growth of US$ 2 Billion from 2023 to 2033. The market in the United States has grown at a CAGR of 14.8% from 2018 to 2022 and is expected to grow at a CAGR of 17.4% from the year 2023 to 2033.
In 2018, with over 9.6 million deaths, cancer was the second leading cause of death globally. Metagenomics sequencing can be used to analyze the microbiome which is the collection of microorganisms and also to analyze tumor DNA which provides information about genetic mutations. It also helps in diagnosing and guides the treatment of cancer. This is expected to influences the market growth.
United Kingdom Metagenomic Sequencing Market Analysis :
The market in the United Kingdom is expected to grow to be worth US$ 321.7 million by 2033, with an absolute dollar growth of US$ 253.4 million. The market in the United Kingdom has grown at a CAGR of 13.7% from 2018 to 2022 and is expected to grow at a CAGR of 16.8% from 2023 to 2033.
According to research, in 2019 around 105 thousand people were diagnosed with HIV and 229 people died due to HIV in the United Kingdom. Overall, Metagenomic sequencing has the potential to the advanced diagnosis of HIV and improves treatment and prevention strategies. The increase in the incidence of HIV, influences the market growth.
China Metagenomic Sequencing Market Analysis :
In China, the market is expected to grow to be worth US$ 620.3 million with an absolute dollar growth of US$ 490.9 million. The market in China has grown at a CAGR of 14.3% from 2018 to 2022 and is expected to grow at a CAGR of 17% from 2023 to 2033.
According to official data from the Chinese government, China was the first country to report cases of COVID-19. In 2020, about 91 thousand cases were diagnosed and over 4 thousand patients died due to COVID-19. Metagenomic sequencing helps with the detection and characterization of SARS-CoV-2 and develops diagnostic tests and other tools for outbreak management. Thus the market in China grew at a significant pace with the onset of Covid-19 in the country.
Japan Metagenomic Sequencing Market Analysis :
In Japan, the market is expected to grow to be worth US$ 347.9 million with an absolute dollar growth of US$ 264.4 Million. The market in the country has grown at a CAGR of 12% from 2018 to 2022 and is expected to grow at a CAGR of 15.3% from the year 2023 to 2033.
According to World Health Organisation (WHO), there were over 94 thousand lung cancer cases diagnosed and around 71 thousand deaths were reported in 2018. Lung cancer is the leading cause of death in Japan. Metagenomic sequencing can detect genetic mutations and other alterations in cancer cells, which can help in treatment decisions and disease progression monitoring.
India Metagenomic Sequencing Market Analysis :
The market in India is expected to grow to be worth US$ 190.8 million by 2033, with an absolute dollar growth of US$ 141.8 million. The market in the country has grown at a CAGR of 11.1% from 2018 to 2022 and is expected to grow at a CAGR of 14.6% from 2023 to 2033.
According to the National AIDS Control Organization (NACO), in 2018, over 2.1 million cases were diagnosed and 69 thousand people died due to HIV in India. Metagenomic sequencing is used for the diagnosis, prevention, and treatment of HIV. The increase in the cases of HIV is expected to influences the market growth in the forthcoming years.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Why Market Revenue through Reagents and Consumables is projected to Witness Significant Growth?
The demand for reagents and consumables is projected to witness significant growth with a CAGR of 15.1% from 2018 to 2022 and is expected to grow at a CAGR of 17.4% from 2023 to 2033.
Reagents and consumables are essential materials used in various laboratory procedures and experiments. Reagents and consumables are convenient, cost-effective, specialized for specific applications, and designed with safety features, and they can improve the accuracy of experimental results. Thus, demand through reagents and consumables is projected to witness significant growth in revenue.
The factors include the development and commercialization of high-quality reagents and kits, DNA extraction kits, bioinformatics software, library preparation kits, sequencing reagents, and continuous reagents by end users.
Through which Application is the Market projected to Witness Significant Growth?
The market through drug discovery application is projected to witness significant growth with a CAGR of 14.8% from 2018 to 2022 and 16.9% from 2023 to 2033.
Drug discovery is the process of identifying and developing new medications for the treatment of various diseases and medical conditions. The significant market share of this sector can be linked to the expansion of research initiatives for the discovery of novel drugs and of market participants, academic institutions, and pharmaceutical firm’s drug development partnerships.
Competitive Analysis :
Key players in the market are Illumina, Inc., Thermo Fisher Scientific, QIAGEN, PerkinElmer, Inc., Oxford Nanopore Technologies Plc., Pacific Biosciences of California, Inc., BGI Group, Psamogen, Inc., Eurofins Scientific, Azenta Life Sciences, Novogen Co. Ltd., Zymo Research Corporation, Tecan Trading AG, Integragen SA, and Microsynth AG.
A few of the recent developments in the market are :
- In July 2021, Pacific Biosciences announced a partnership with Invitae, a prominent medical genetics company. Through this partnership, PacBio's long-read sequencing technology and Invitae's experience with clinical genetic testing will be combined to create a high-throughput sequencing platform for genetic testing.
- In February 2021, Thermo Fisher announced a partnership with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop a companion diagnostic test for cancer drug. The test will use Thermo Fisher's NGS technology to identify patients who are likely to respond to the drug.
- In December 2020, Illumina acquired Pacific Biosciences for approximately US$ 1.2 billion. It is expected to bring together the strengths of both companies in the field of DNA sequencing.
Segmentation of the Metagenomic Sequencing Market :
By Product & Service :
- Reagents & Consumables
- Analysis & Data Interpretation Solutions
By Workflow :
- Sample Processing & Library Preparation
- Data Processing & Analysis
By Technology :
- Shotgun Metagenomic Sequencing
- 16S rRNA Sequencing
- Whole-genome Sequencing & De Novo Assembly
By Application :
- Drug Discovery
- Clinical Diagnostics
- Soil Microbiome Application
- Industrial Applications
- Ecology and Environmental Applications
- Veterinary Applications
- Other Applications
By Region :
- North America
- Latin America
- Asia Pacific
- Middle East & Africa
- FAQs -
The global market size is estimated to be valued at US$ 1.4 Billion in 2023.
The market was reported at US$ 1.2 Billion in 2022.
The market is expected to reach a valuation of US$ 7.1 Billion in 2033.
The market registered a CAGR of 15.3% over the last 4 years.
The market is projected to witness a CAGR of 17.6% from 2023 to 2033.
The market revenue through reagents & consumables is projected to witness large demand with a projected CAGR of 17.4% from 2023 to 2033.
Drug discovery is top application in the market which is projected to witness significant demand with a projected CAGR of 16.9% from 2023 to 2033.
The market in the United States is projected to witness a market size of US$ 2.5 Billion and is expected to grow at a 17.4% CAGR from 2023 to 2033.
Key players in the market are Illumina, Inc., Thermo Fisher Scientific, QIAGEN, PerkinElmer, Inc., Oxford Nanopore Technologies Plc., Pacific Biosciences of California, Inc., BGI Group, Psamogen, Inc., Eurofins Scientific, Azenta Life Sciences, Novogen Co